Operating cash flow to net income ranged widely from 0.31 to 2.68, and the latest free cash flow margin of 9.4% against a $1.1B quarterly dividend outflow suggests shareholder distributions are absorbing much of the cash generated in weaker quarters.
Abbott Laboratories (ABT) cash flow statement — 30-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Cash from Operations | 8.86B | 9.57B | 8.56B | 7.26B | 9.58B | 10.53B | 7.9B | 6.14B | 6.3B | 5.57B | 3.2B | 2.97B | 3.67B | 3.32B | 9.31B | 8.97B | 8.74B | 7.28B | 7.34B | 5.18B | 5.33B | 5.17B | 4.41B | 3.75B | 4.18B | 3.57B | 3.1B | 2.94B | 2.73B | 2.63B | 2.38B |
| Operating CF Margin % | - | 21.58% | 20.4% | 18.1% | 21.95% | 24.45% | 22.83% | 19.23% | 20.6% | 20.34% | 15.36% | 14.54% | 18.15% | 15.21% | 23.36% | 23.09% | 24.84% | 23.65% | 24.87% | 20% | 23.71% | 23.16% | 22.4% | 19.04% | 23.65% | 21.9% | 22.55% | 22.29% | 21.9% | 22.12% | 21.63% |
| Operating CF Growth % | -7.74% | 11.78% | 17.86% | -24.21% | -9.04% | 33.31% | 28.76% | -2.6% | 13.11% | 73.9% | 7.99% | -19.29% | 10.56% | -64.31% | 3.84% | 2.68% | 20.08% | -0.94% | 41.67% | -2.73% | 2.99% | 17.39% | 17.66% | -10.44% | 17.27% | 15.07% | 5.52% | 7.49% | 3.96% | 10.36% | 21.19% |
| Net Income | 4.7B | 6.52B | 13.4B | 5.72B | 6.93B | 7.07B | 4.5B | 3.69B | 2.37B | 477M | 1.38B | 1.58B | 2.28B | 2.58B | 5.96B | 4.73B | 4.63B | 5.75B | 4.73B | 3.61B | 1.72B | 3.37B | 3.18B | 2.75B | 2.79B | 1.55B | 2.79B | 2.45B | 2.33B | 2.09B | 1.88B |
| Depreciation & Amortization | 3.79B | 3.12B | 3.22B | 3.24B | 3.27B | 3.54B | 3.33B | 3.01B | 3.28B | 3.02B | 1.35B | 1.47B | 1.55B | 1.72B | 2.78B | 3.04B | 2.62B | 2.09B | 1.84B | 1.85B | 1.56B | 1.36B | 1.29B | 1.27B | 1.18B | 1.17B | 827.43M | 828.01M | 784.24M | 727.75M | 686.09M |
| Stock-Based Compensation | 735M | 664M | 673M | 644M | 685M | 640M | 546M | 519M | 477M | 406M | 310M | 292M | 246M | 262M | 433M | 383M | 387.18M | 366.36M | 347.01M | 46.33M | 136.47M | 9.74M | -10.22M | -7.66M | 11.72M | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 293M | -1.16B | 248M | 314M | 429M | 395M | 1.85T | 968.76B | 328.41B | 508.67B | 1.01B | -4.77M | -44.51M | 65.35M | -70.22M | 28.79M | 2.62M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -217M | 65M | 482M | 126M | 215M | 55M | 425M | 247M | 32M | 912M | 1.43B | -539M | -342M | -391M | -1.85T | -967.94B | -327.97B | -509.25B | -545.03M | 744.45M | 2.51B | 194.38M | 508.76M | 194.91M | 227.84M | 1.49B | -68.59M | 83.71M | 76.62M | 145.02M | 53.8M |
| Working Capital Changes | -155M | -803M | -9.22B | -2.48B | -1.52B | -771M | -892M | -1.33B | -148M | 1.92B | -1.51B | -156M | -490M | -1.24B | -1.86B | 1.07M | 658.78M | -341.38M | -39.69M | -1.06B | -548.06M | 173.94M | -484.92M | -496.82M | -30.28M | -641.9M | -445.2M | -419.96M | -461.19M | -338.46M | -239.86M |
| Change in Receivables | -682M | -652M | -691M | -356M | -68M | -383M | -924M | -275M | -190M | -207M | -177M | -171M | -195M | -113M | 36M | -670.15M | -394.67M | -387.75M | -948.31M | 12.89M | 21.07M | -158.98M | 75.44M | 40.57M | -137.71M | -279.17B | -260.79M | 0 | 0 | 0 | 0 |
| Change in Inventory | -538M | 195M | -58M | -232M | -1.41B | -456M | -493M | -593M | -514M | 249M | -98M | -257M | -297M | -154M | -417.05M | -129.62M | 139.86M | 230.56M | -257.48M | 131.32M | 104.65M | -88.26M | -285.33M | 7.01M | -190.97M | -184.95M | -361.38M | -147.78M | -111.65M | -98.96M | -125.73M |
| Change in Payables | 0 | 954M | 356M | -760M | 420M | 1.29B | 1.77B | 220M | 747M | 615M | -652M | -742M | -225M | -436M | -134.21M | 1.79B | 572.53M | -374.71M | 569.06M | -59.38M | -80.09M | -62.43M | -99.93M | -17.79M | 56.67M | 732.48B | 621.08M | 0 | 0 | 0 | 0 |
| Cash from Investing | -22.3B | -2.42B | -2.34B | -3.13B | -1.74B | -2.01B | -2.21B | -1.81B | -1.36B | -9.62B | -248M | 406M | -202M | -3.93B | -6.08B | 260.83M | -12.19B | -3.7B | -2.09B | -1.14B | -11.4B | -720.09M | -3.92B | -1.63B | -1.88B | -8.38B | -617.66M | -1.2B | -1.42B | -1.2B | -1.96B |
| Capital Expenditures | -2.1B | -2.17B | -2.21B | -2.2B | -1.78B | -1.89B | -2.18B | -1.64B | -1.39B | -1.14B | -1.12B | -1.11B | -1.08B | -1.15B | -1.8B | -1.49B | -1.02B | -1.09B | -1.29B | -1.66B | -1.34B | -1.21B | -1.29B | -1.25B | -1.3B | -1.16B | -1.04B | -987.1M | -1.24B | -1.21B | -949M |
| CapEx % of Revenue | 4.35% | 4.9% | 5.26% | 5.49% | 4.07% | 4.38% | 6.29% | 5.13% | 4.56% | 4.14% | 5.38% | 5.44% | 5.32% | 5.24% | 4.5% | 3.84% | 2.89% | 3.54% | 4.36% | 6.39% | 5.95% | 5.41% | 6.56% | 6.33% | 7.33% | 7.15% | 7.54% | 7.49% | 9.96% | 10.18% | 8.62% |
| Acquisitions | -20.13B | -105M | 1M | -837M | 48M | -53M | 16M | -122M | 48M | -8.44B | -55M | 2.29B | -3.32B | -580M | -1.23B | -672.5M | -9.43B | -2.37B | -250M | 0 | -7.92B | -295.12M | -2.33B | -497.91M | -586M | -7.42B | 205M | -217M | -1.24B | -1.21B | -1.78B |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 59M | 18M | 9M | 22M | 22M | 26M | 19M | 27M | 48M | 35M | 42M | 52M | 75M | 21M | 2.72M | 1.89B | -1.89B | -6.37M | -75.06M | -33.48M | -25.71M | 14.6M | 14.43M | 66.47M | 16.57M | -308.78B | 45.45M | 12.19M | 18.03M | -8.21M | 19.1M |
| Cash from Financing | 9.99B | -6.31B | -5.4B | -7.09B | -7.64B | -5.49B | -2.78B | -4.29B | -10.39B | -5.28B | 11.15B | -2.24B | -2.74B | -6.7B | 716.09M | -6.02B | -1.09B | 1B | -3.49B | -2.31B | 3.62B | -2.59B | -438.32M | -2.01B | -2.31B | 4.62B | -2.15B | -1.43B | -1.23B | -1.31B | -592.29M |
| Debt Issued (Net) | 15.53B | -1.61B | -537M | -2.48B | -699M | -248M | -50M | -1.6B | -8.45B | -1.91B | 13.15B | 1.15B | 766M | 1.79B | 4.41B | -3.98B | 2.12B | 3.73B | -1.24B | -544.49M | 5.65B | 172.83M | 806M | -467.93M | -1.02B | 5.74B | -672.77M | -857.7M | 382.4M | 417.3M | 835M |
| Equity Issued (Net) | -1.31B | -497M | -1.29B | -1.23B | -3.79B | -2.3B | -403M | -718M | -238M | -477M | -522M | -2.24B | -2.19B | -1.6B | -2.36B | 891.75M | -866.83M | -826.35M | -1.08B | 191.01M | -251.72M | -1.08B | -344.55M | -22.58M | 137M | 152.06M | -329.29M | 434.2M | -723.9M | -896.7M | -699.2M |
| Dividends Paid | -4.32B | -4.12B | -3.84B | -3.56B | -3.31B | -3.2B | -2.56B | -2.27B | -1.97B | -1.85B | -1.54B | -1.44B | -1.34B | -882M | -3.18B | -2.94B | -2.67B | -2.41B | -2.17B | -1.96B | -1.78B | -1.69B | -1.6B | -1.52B | -1.43B | -1.27B | -1.15B | -1B | -891.7M | -809.6M | -728.1M |
| Share Repurchases | -1.54B | -893M | -1.29B | -1.23B | -3.79B | -2.3B | -403M | -718M | -238M | -827M | -522M | -2.24B | -2.19B | -1.6B | -2.36B | -77.01M | -866.83M | -826.35M | -1.08B | -1.06B | -754.5M | -1.3B | -499.75M | -97.62M | 0 | -17.36M | -464.86M | 0 | -876.3M | -1.05B | -808.8M |
| Other Financing | 100M | -82M | 264M | 167M | 167M | 255M | 234M | 298M | 271M | -1.05B | 53M | 297M | 29M | -6B | 1.33B | -96K | 328.41M | 508.67M | 1.01B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -26K | 0 | 0 | 0 |
| Net Change in Cash | -3.46B | 906M | 720M | -2.99B | 83M | 2.96B | 2.98B | 16M | -5.56B | -9.21B | 13.62B | 938M | 588M | -7.33B | 3.99B | 3.16B | -5.16B | 4.7B | 1.66B | 1.94B | -2.37B | 1.67B | 230.5M | 290.67M | 47.07M | -256.84M | 306.12M | 292.86M | 78.21M | 119.81M | -170.99M |
| Free Cash Flow | 7.65B | 7.39B | 6.35B | 5.06B | 7.8B | 8.65B | 5.72B | 4.5B | 4.91B | 4.43B | 2.08B | 1.86B | 2.6B | 2.18B | 7.52B | 7.48B | 7.72B | 6.19B | 6.06B | 3.53B | 3.99B | 3.97B | 3.12B | 2.5B | 2.89B | 2.4B | 2.06B | 1.95B | 1.49B | 1.42B | 1.43B |
| FCF Margin % | 15.87% | 16.68% | 15.14% | 12.61% | 17.88% | 20.08% | 16.54% | 14.1% | 16.04% | 16.19% | 9.98% | 9.1% | 12.83% | 9.97% | 18.86% | 19.25% | 21.95% | 20.11% | 20.51% | 13.61% | 17.76% | 17.76% | 15.83% | 12.7% | 16.32% | 14.76% | 15.01% | 14.8% | 11.94% | 11.94% | 13.01% |
| FCF Growth % | 10.64% | 16.44% | 25.54% | -35.17% | -9.76% | 51.08% | 27.26% | -8.32% | 10.62% | 113.02% | 12.18% | -28.56% | 19.23% | -71.02% | 0.54% | -3.14% | 24.81% | 2.14% | 71.69% | -11.62% | 0.62% | 27.3% | 24.67% | -13.4% | 20.12% | 16.45% | 5.81% | 30.88% | 5.01% | -0.97% | -27.09% |
| FCF per Share | 4.40 | 4.23 | 3.63 | 2.89 | 4.42 | 4.83 | 3.20 | 2.53 | 2.77 | 2.54 | 1.40 | 1.23 | 1.70 | 1.38 | 4.72 | 4.76 | 4.96 | 3.98 | 3.88 | 2.26 | 2.60 | 2.54 | 1.98 | 1.59 | 1.83 | 1.53 | 1.32 | 1.25 | 0.95 | 0.90 | 0.91 |
| FCF Conversion (FCF/Net Income) | 1.63x | 1.47x | 0.64x | 1.27x | 1.38x | 1.49x | 1.76x | 1.66x | 2.66x | 11.68x | 2.29x | 0.67x | 1.61x | 1.29x | 1.56x | 1.90x | 1.89x | 1.27x | 1.50x | 1.44x | 3.10x | 1.53x | 1.36x | 1.36x | 1.50x | 2.30x | 1.11x | 1.20x | 1.17x | 1.26x | 1.27x |
| Interest Paid | 0 | 0 | 604M | 662M | 563M | 544M | 549M | 677M | 845M | 917M | 181M | 166M | 146M | 148M | 576M | 545M | 580.17M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 1.72B | 1.48B | 1.86B | 1.94B | 970M | 930M | 740M | 570M | 620M | 631M | 448M | 1.04B | 1.37B | 1.78B | 809.71M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ABT stock.
Abbott Laboratories (ABT) generated $9.57B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Abbott Laboratories (ABT) generated $7.39B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Abbott Laboratories (ABT) spent $2.17B on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Abbott Laboratories (ABT) returned $4.12B to shareholders via cash dividends and spent $893.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Quarterly cash flow volatility and acquisition outflows
Metrics are mathematically derived from official filings.
Cash Conversion Swings Obscure Earnings Quality
According to the reported quarterly cash flow statements, ABT's operating cash flow to net income ratio ranged from 0.31 in Q4 2024 to 2.68 in Q2 2026, a dispersion that suggests reported earnings are heavily affected by working capital timing rather than steady underlying cash generation across the ten quarters reviewed.
The Q4 2024 ratio of 0.31, driven by a roughly $8.4B working capital outflow against $9.2B of net income, indicates that the reported profit that quarter was largely offset by balance sheet movements that may warrant further investigation. Conversely, the elevated ratios in 2026 Q2 and 2025 Q4 appear to reflect working capital release rather than structurally superior earnings quality. Investors should monitor whether the trailing average conversion settles near the 1.2 to 1.9 range seen in most quarters, which would be more consistent with the company's reported profitability profile.
Free Cash Flow Margins Remain Volatile
Based on reported figures, ABT's free cash flow margin moved between 8.2% and 22.9% across the ten quarters, with the most recent quarter at 9.4%, a range that suggests cash generation is more sensitive to timing items than to a stable operating run-rate.
The compression to 9.4% in 2026 Q3 from 22.9% in 2026 Q2 reflects a working capital swing of roughly -$576M against a rebound in operating cash flow, which implies the headline FCF figure may overstate or understate sustainable generation depending on the quarter. Averaging across the window produces a mid-teens margin that appears more representative of the underlying business than any single quarter. The trajectory warrants monitoring for whether the 2026 Q2 spike was a one-time release or the start of a sustained step-up.
Capital Intensity Stays Modest Relative to Revenue
As reported in the quarterly cash flow statements, ABT's capital expenditures ran between 3.6% and 6.6% of revenue across the period, with recent quarters clustering near 3.6% to 3.9%, a level that appears light for a diversified medical device and diagnostics manufacturer.
Capex of roughly $400M to $720M per quarter against D&A of approximately $730M to $810M in most periods indicates the company has been spending close to, and at times below, its depreciation base, which may suggest either efficient utilization of existing plant or underinvestment in replacement capacity. The 2026 Q1 and Q3 readings near $400M to $510M sit below the 2024 and 2025 run-rate, and investors should watch whether that reduction reflects completed manufacturing build-outs or deferred maintenance needs.
Dividend Commitment Dominates Recurring Outflows
According to the reported cash flow data, ABT paid roughly $958M to $1.1B in dividends in each quarter of the window, a steady outflow that consumed much of free cash flow in weaker quarters such as 2026 Q1 and 2025 Q1.
In quarters where FCF fell to roughly $916M to $933M, dividends absorbed nearly all of the generated cash, leaving little residual capacity for buybacks or debt reduction without external funding. Acquisition outflows were lumpy, including an unusually large $19.8B figure in 2026 Q1 that appears to be a major transaction and warrants further investigation into its strategic rationale and financing. The pattern suggests capital allocation is weighted toward the dividend and episodic large acquisitions rather than a predictable repurchase program.
Cumulative Cash Gap Reflects Working Capital Noise
Based on the ten reported quarters, cumulative operating cash flow appears to exceed cumulative net income, but this gap is heavily influenced by a single $8.4B working capital outflow in Q4 2024 that may distort any simple long-run comparison.
Excluding the Q4 2024 working capital distortion, operating cash flow tracked net income at a ratio that appears comfortably above 1.0 in most periods, which suggests the underlying business generates cash in excess of reported earnings after non-cash charges such as D&A. The divergence is therefore less a signal of earnings inflation than of timing volatility in receivables, inventory, and payables. Investors should avoid drawing firm conclusions about earnings quality from any short window without extending the analysis across a full cycle.
Cash Flow Statement May Understate Structural Pressures
Based on reported figures, the bear case rests on operating margin compression to roughly 10% in the latest quarter alongside legal exposure accounting for about 32% of tracked risk factors, which may indicate cash generation is flattered by working capital timing that could reverse.
If the strong 2026 Q2 operating cash flow of $2.5B was supported by a $734M working capital release rather than durable earnings, the subsequent normalization seen in 2026 Q3 could represent the underlying run-rate rather than an anomaly. Litigation and product-related claims, particularly in pediatric nutrition, may not be fully reflected in the reported cash flow figures and warrant further investigation into any reserves or contingent payments. Investors should consider whether the dividend and episodic acquisition outflows remain sustainable if operating cash flow reverts toward the lower end of the observed range.